Payment overview · 2025
General Payments
$3,830.10
134 reported records · 27 companies
Healthcare provider profile · identity verified
Amber Ladner, FNP- C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GULFPORT, MS · NPI 1659003580
Verified facts
What the public records show
CMS Open Payments records show Amber Ladner, FNP- C received $3,830.10 in general payments during 2025 across 134 reported records.
Abbott Laboratories accounted for 46.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ubrelvy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Nurtec Odt by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,792.61 | 46.8% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $404.58 | 10.6% | 23 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $304.92 | 8.0% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $211.98 | 5.5% | 22 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $138.00 | 3.6% | 11 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $135.51 | 3.5% | 8 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $97.49 | 2.5% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $79.22 | 2.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.41 | 1.9% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $71.92 | 1.9% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $70.07 | 1.8% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $60.46 | 1.6% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$57.27 | 1.5% | 3 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $43.82 | 1.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $39.17 | 1.0% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $38.28 | 1.0% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $23.05 | 0.6% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.40 | 0.6% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $21.30 | 0.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.25 | 0.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.03 | 0.6% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$19.87 | 0.5% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.21 | 0.5% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.19 | 0.5% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.51 | 0.5% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.77 | 0.4% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $13.81 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,551.80 | 127 |
| Travel and Lodging | $1,245.80 | 5 |
| Education | $32.50 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $1,245.80 | 5 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $411.68 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $244.43 | 12 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $183.94 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $176.09 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $145.29 | 10 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $135.13 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $132.33 | 9 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $110.24 | 9 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $104.47 | 8 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $97.49 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $79.22 | 4 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $78.67 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $77.58 | 11 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $73.41 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $71.92 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $70.07 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $60.46 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $39.47 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.76 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | MDD US Operations, LLC | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $10.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 134 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 147 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
147 | 42 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
134 | 30 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 388 | 136 |
| Levetiracetam | Levetiracetam | 321 | 89 |
| Donepezil Hcl | Donepezil Hcl | 239 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 69 |
| Topiramate | Topiramate | 156 | 51 |
| Memantine Hcl | Memantine Hcl | 152 | 58 |
| Pregabalin | Pregabalin | 148 | 50 |
| Ubrelvy | Ubrogepant | 147 | 42 |
| Sertraline Hcl | Sertraline Hcl | 136 | 63 |
| Nurtec Odt | Rimegepant Sulfate | 134 | 30 |
| Primidone | Primidone | 121 | 38 |
| Lacosamide | Lacosamide | 100 | 22 |
| Lamotrigine | Lamotrigine | 98 | 28 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 92 | 35 |
| Emgality Pen | Galcanezumab-Gnlm | 83 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 35 |
| Sumatriptan Succinate | Sumatriptan Succinate | 76 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 25 |
| Propranolol Hcl | Propranolol Hcl | 64 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 29 |
| Divalproex Sodium | Divalproex Sodium | 58 | 30 |
| Baclofen | Baclofen | 57 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 27 |
| Buspirone Hcl | Buspirone Hcl | 51 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 45 | 16 |
| Carbamazepine Er | Carbamazepine | 40 | suppressed |
| Qulipta | Atogepant | 40 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | 11 |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 30 | suppressed |
| Zonisamide | Zonisamide | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Lorazepam | Lorazepam | 22 | 19 |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 19 | suppressed |
| Briviact | Brivaracetam | 18 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 17 | suppressed |
| Tetrabenazine | Tetrabenazine | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Furosemide | Furosemide | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,830.10 · 134 records | Abbott Laboratories | ACTHAR, AMYVID, AUSTEDO XR, BOTOX, BRIUMVI, Bafiertam, Briviact, ELYXYB - CELECOXIB, ETERNA, Fintepla, HYQVIA, KISUNLA, Kerendia, Leqembi, MOUNJARO, NURTEC ODT, PROCLAIM, PURIFIED CORTROPHIN GEL, QULIPTA, Qelbree, REXULTI, Rystiggo, Symbravo, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VYALEV, VYEPTI, VYVGART HYTRULO, ZAVZPRET, ZEPBOUND, ZEPOSIA, Zilbrysq | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error